Baxter International Inc.

Baxter Healthcare Sa

Leukocare Ag

Heinz Gulle

Andreas Goessl

Monika Mangold

Melitta Bilban

John J Barry

Katarzyna Gorna

Joris Hoefinghoff

Rahul Kumar Singh

Eva Reinauer

Stella Grosso

Julia Rabas

Katarzyna I Gorna

Disclosed are a fibrinogen solution and a thrombin solution. The fibrinogen solution comprises fibrinogen at a concentration of at least 40 mg/ml, factor XIII, pharmaceutically acceptable additives and water. The dynamic viscosity of the fibrinogen solution measured at 20° C. increases at most by 35% after storing the solution at 20° C. for 30 days. The thrombin solution comprises thrombin, pharmaceutically acceptable additives and water. The thrombin activity decreases at most by 15% after storing the solution at 25° C. for 14 days. Also disclosed is a fibrin sealant kit with a first container comprising the fibrinogen solution and a second container comprising the thrombin solution. Further, methods for preparing a fibrin sealant and methods for treating a wound are disclosed.

Fibrinogen and thrombin solutions for a fibrin sealant and fibrin sealant kit

The invention discloses a hemostatic composition comprising:

Hemostatic compositions

The present invention relates to a biodegradable injectable composition for bone augmentation comprising fibrin, a contrast agent and calcium salt-containing particles, as well as a method for bone augmentation in a patient suffering from a bone disorder comprising injecting said composition into a non-mineralized or hollow portion of said bone.

Injectable fibrin composition for bone augmentation

Bone hemostat compositions, and methods for their use and manufacture are provided. Exemplary hemostatic compositions include polymeric components such as random and non-random copolymers, natural polymers, ceramics, reactive group polymers, and combinations thereof. Bone compositions may be used during surgical procedures, and may be applied to bone to inhibit or prevent bleeding from bone.

Aqueous compositions and methods for bone hemostasis

The present invention teaches a micro-porous injectable, soft elastic, fully resorbable fibrin-based composition for use as a soft tissue lumen and void filler. The composition of the present application exhibits physical characteristics, such as mechanical properties, typically seen in elastomers and mechanical stability, which is superior to fibrin alone. A variety of properties of the composition of the present invention can be effectively fine-tuned and altered by adjusting type and content of the particles as well as of the plasticizer contained in the void filler composition.

Injectable void filler for soft tissue augmentation

The present invention relates to a biodegradable fibrin based composition for injection into osseous defects or voids, which can be the result of osteoporosis, surgery, bone cysts, tumor removal or traumatic bone injury.

Growing community of inventors

Gross Enzersdorf, Austria

Heinz Gulle